Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Sosei Group ( (JP:4565) ).
Nxera Pharma has completed a tender offer to repurchase ¥5 billion in principal amount of its euro-yen denominated convertible bonds due 2028, paying a total of approximately ¥4.84 billion excluding accrued interest, based on a slight discount to face value. Following the transaction, ¥27 billion in principal amount of the convertible bonds remains outstanding, indicating a targeted balance-sheet action that may modestly reduce future potential dilution for shareholders while maintaining significant outstanding convertible debt.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen718.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing and commercializing specialty medicines for patients with unmet medical needs in Japan and globally. Through its agile commercial business in Japan and broader APAC, and its NxWave discovery platform, the company is advancing a pipeline of over 30 programs across obesity and metabolic disorders, neurology and neuropsychiatry, and immunology and inflammation, operating from hubs in Japan, the UK, Switzerland and South Korea and listed on the Tokyo Stock Exchange.
YTD Price Performance: -28.05%
Average Trading Volume: 826,780
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen68.23B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.